update 2 instruction

core/hbv_assessment.py

@@ -290,7 +290,8 @@ CRITICAL ELIGIBILITY HIERARCHY:
     * If patient has **HBV-HCV coinfection** AND meets HBV treatment criteria (Page 9): Set **"eligible": true"**.
 2.  **Check Standard Criteria SECOND (Page 6):**
     * If *not* eligible based on special populations, check standard criteria (HBV DNA, ALT, fibrosis, age, family history).
-    * If any Page 6 criteria are met (e.g., Cirrhosis, or HBV DNA > 2,000 + ALT > ULN + moderate fibrosis, etc.): Set **"eligible": true"**.
+    * For **HBeAg-negative** patients with **HBV DNA < 2,000 IU/mL** and **ALT ≤ ULN**, and **no cirrhosis** and **no special-population indication**, you MUST classify as **not eligible** and recommend monitoring only, even if fibrosis is moderate (F2–F3). Use Page 6 for thresholds and Page 7 for monitoring.
+    * If any other Page 6 criteria are met (e.g., Cirrhosis, or HBV DNA > 2,000 + ALT > ULN + moderate fibrosis, etc.): Set **"eligible": true"**.
 3.  **If NO criteria from (1) or (2) are met:** Set **"eligible": false"**.
 4.  The "eligible" flag MUST be consistent with the "Eligibility and Rationale" bullet. Do not contradict yourself.
 
@@ -333,7 +334,7 @@ EXAMPLE OUTPUT (ELIGIBLE - STANDARD CRITERIA) - Use SINGLE \\n only:
 EXAMPLE OUTPUT (NOT ELIGIBLE - STANDARD CRITERIA) - Use SINGLE \\n only:
 {{
   "eligible": false,
-  "recommendations": "Eligibility and Rationale:\\n- Not eligible: HBV DNA < 2,000 IU/mL, ALT ≤ ULN, no significant fibrosis [SASLT 2021, Page 6]\\nTreatment Recommendations:\\n- Treatment not indicated at this time [SASLT 2021, Page 6]\\nMonitoring and Follow-up:\\n- Monitor every 6-12 months (HBeAg-negative, HBV DNA < 2,000 IU/mL) (Grade B) [SASLT 2021, Page 7]\\nReferences:\\n- Pages 6, 7: Treatment criteria, monitoring protocols"
+  "recommendations": "Eligibility and Rationale:\\n- Not eligible: HBV DNA < 2,000 IU/mL, ALT ≤ ULN, moderate fibrosis (F2–F3) [SASLT 2021, Page 6]\\nTreatment Recommendations:\\n- Treatment not indicated at this time [SASLT 2021, Page 6]\\nMonitoring and Follow-up:\\n- Monitor every 6-12 months (HBeAg-negative, HBV DNA < 2,000 IU/mL) (Grade B) [SASLT 2021, Page 7]\\nReferences:\\n- Pages 6, 7: Treatment criteria, monitoring protocols"
 }}
 ---
 EXAMPLE OUTPUT (ELIGIBLE - IMMUNOSUPPRESSION) - Use SINGLE \\n only: